Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

@article{Khanna2009RecombinantHR,
  title={Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.},
  author={Dinesh Khanna and Philip J. Clements and Daniel e. Furst and Joseph H. Korn and Michael H Ellman and Naomi F. Rothfield and Fredrick Wigley and Larry Moreland and Richard I Silver and Youn Hee Kim and Virginia D. Steen and Gary S. Firestein and Arthur F. Kavanaugh and Michael D Weisman and Maureen D. Mayes and David H. Collier and Mary Ellen Csuka and Robert W. Simms and Peter A. Merkel and Thomas A Jr Medsger and Martin E. Sanders and Paul M Maranian and James R. Seibold},
  journal={Arthritis and rheumatism},
  year={2009},
  volume={60 4},
  pages={
          1102-11
        }
}
OBJECTIVE A phase II randomized controlled trial of recombinant human relaxin suggested that a dosage of 25 microg/kg/day was safe and clinically effective in improving skin disease and reducing functional disability in scleroderma (systemic sclerosis; SSc). We undertook a large randomized, double-blind, placebo-controlled clinical trial to compare placebo with 10 microg/kg/day and 25 microg/kg/day recombinant human relaxin, given for 24 weeks in patients with stable, diffuse, moderate-to… CONTINUE READING
Highly Cited
This paper has 42 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references